BMS Reports ‘Clinically Meaningful’ PFS Benefit In Topline Confirmatory Results For Krazati

Amgen’s Lumakras had hit a snag when the FDA questioned its confirmatory trial in the same indication, particularly the marginal PFS benefit and lack of OS benefit.